ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.
about
Icariside II induces cell cycle arrest and apoptosis in human glioblastoma cells through suppressing Akt activation and potentiating FOXO3a activity.Induction of anti-EGFR immune response with mimotopes identified from a phage display peptide library by panitumumabAdvances in immunotherapy for the treatment of glioblastoma.Vaccination in the immunotherapy of glioblastoma.Current and emerging EGFR therapies for glioblastoma.
P2860
ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
ReACT Phase II trial: a critic ...... sitive recurrent glioblastoma.
@en
type
label
ReACT Phase II trial: a critic ...... sitive recurrent glioblastoma.
@en
prefLabel
ReACT Phase II trial: a critic ...... sitive recurrent glioblastoma.
@en
P2860
P356
P1433
P1476
ReACT Phase II trial: a critic ...... ositive recurrent glioblastoma
@en
P2093
John F de Groot
Shiao-Pei S Weathers
P2860
P356
10.2217/CNS.15.38
P577
2015-12-15T00:00:00Z